Furthermore, a screening of 133 approved cancer drugs, which included tyrosine kinase inhibitors, HDAC inhibitors, and proteasome inhibitors, the ALK/MET inhibitor crizotinib demonstrated promising potential for standard chemotherapy regimens for chordomas [13]. This evidence concerns the gene HDAC9 and chordoma.